Literature DB >> 4052972

Regression in malignant melanoma. A histologic feature without independent prognostic significance.

J W Kelly, R W Sagebiel, M S Blois.   

Abstract

A total of 844 cutaneous malignant melanomas were examined prospectively for the presence or absence of histologic regression within the primary tumor. Cases were then stratified into three groups according to tumor thickness and survival was compared between substrata with and without regression in each group. The distribution of other major prognostic variables within these substrata was assessed and their influence as potential confounding variables considered. No statistically significant effect of regression on survival was found in any of the three thickness strata. These results do not confirm the finding of an earlier study, which suggested that regression may be a poor prognostic sign when found in association with thin malignant melanomas. Regression was almost invariably associated with the radial growth phase of melanomas. Regression was more common in male than in female patients, and was more frequent in association with truncal than extremity or head and neck melanomas.

Entities:  

Mesh:

Year:  1985        PMID: 4052972     DOI: 10.1002/1097-0142(19851101)56:9<2287::aid-cncr2820560924>3.0.co;2-y

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  15 in total

1.  The significance of inflammation and regression in melanoma.

Authors:  M G Cook
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

Review 2.  Regressing thin cutaneous malignant melanomas (< or = 1.0 mm) are associated with angiogenesis.

Authors:  R L Barnhill; M A Levy
Journal:  Am J Pathol       Date:  1993-07       Impact factor: 4.307

3.  Regression in primary cutaneous melanoma: etiopathogenesis and clinical significance.

Authors:  Phyu P Aung; Priyadharsini Nagarajan; Victor G Prieto
Journal:  Lab Invest       Date:  2017-02-27       Impact factor: 5.662

4.  Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database.

Authors:  Richard L White; Gregory D Ayers; Virginia H Stell; Shouluan Ding; Jeffrey E Gershenwald; Jonathan C Salo; Barbara A Pockaj; Richard Essner; Mark Faries; Kim James Charney; Eli Avisar; Axel Hauschild; Friederike Egberts; Bruce J Averbook; Carlos A Garberoglio; John T Vetto; Merrick I Ross; David Chu; Vijay Trisal; Harald Hoekstra; Eric Whitman; Harold J Wanebo; Daniel Debonis; Michael Vezeridis; Aaron Chevinsky; Mohammed Kashani-Sabet; Yu Shyr; Lynne Berry; Zhiguo Zhao; Seng-Jaw Soong; Stanley P L Leong
Journal:  Ann Surg Oncol       Date:  2011-06-07       Impact factor: 5.344

5.  Outcome of sentinel lymph node biopsy and prognostic implications of regression in thin malignant melanoma.

Authors:  Susannah E McClain; Amber L Shada; Megan Barry; James W Patterson; Craig L Slingluff
Journal:  Melanoma Res       Date:  2012-08       Impact factor: 3.599

6.  Cutaneous melanomas exhibiting unusual biologic behavior.

Authors:  H M Shaw; J K Rivers; S W McCarthy; W H McCarthy
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

7.  Clonal T cell responses in tumor infiltrating lymphocytes from both regressive and progressive regions of primary human malignant melanoma.

Authors:  P thor Straten; J C Becker; T Seremet; E B Bröcker; J Zeuthen
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

8.  [Regression in malignant melanoma. Definition, etiopathogenesis, morphology and differential diagnosis].

Authors:  B E Paredes
Journal:  Pathologe       Date:  2007-11       Impact factor: 1.011

9.  Histopathology report of cutaneous melanoma and sentinel lymph node in Europe: a web-based survey by the Dermatopathology Working Group of the European Society of Pathology.

Authors:  Anna Batistatou; Martin G Cook; Daniela Massi
Journal:  Virchows Arch       Date:  2009-04-08       Impact factor: 4.064

10.  Lethal "thin" malignant melanoma. Identifying patients at risk.

Authors:  C L Slingluff; R T Vollmer; D S Reintgen; H F Seigler
Journal:  Ann Surg       Date:  1988-08       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.